BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 37128917)

  • 1. Additive Effect of
    Marmontel O; Abou-Khalil Y; Bluteau O; Cariou B; Carreau V; Charrière S; Divry E; Gallo A; Moulin P; Paillard F; Peretti N; Rabès JP; Varret M; Carrié A; Di Filippo M
    Arterioscler Thromb Vasc Biol; 2023 Jul; 43(7):e270-e278. PubMed ID: 37128917
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Double-heterozygous autosomal dominant hypercholesterolemia: Clinical characterization of an underreported disease.
    Sjouke B; Defesche JC; Hartgers ML; Wiegman A; Roeters van Lennep JE; Kastelein JJ; Hovingh GK
    J Clin Lipidol; 2016; 10(6):1462-1469. PubMed ID: 27919364
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Global molecular analysis and APOE mutations in a cohort of autosomal dominant hypercholesterolemia patients in France.
    Wintjens R; Bozon D; Belabbas K; MBou F; Girardet JP; Tounian P; Jolly M; Boccara F; Cohen A; Karsenty A; Dubern B; Carel JC; Azar-Kolakez A; Feillet F; Labarthe F; Gorsky AM; Horovitz A; Tamarindi C; Kieffer P; Lienhardt A; Lascols O; Di Filippo M; Dufernez F
    J Lipid Res; 2016 Mar; 57(3):482-91. PubMed ID: 26802169
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of mutations in LDLR and PCSK9 genes on phenotypic variability in Tunisian familial hypercholesterolemia patients.
    Slimani A; Jelassi A; Jguirim I; Najah M; Rebhi L; Omezzine A; Maatouk F; Hamda KB; Kacem M; Rabès JP; Abifadel M; Boileau C; Rouis M; Slimane MN; Varret M
    Atherosclerosis; 2012 May; 222(1):158-66. PubMed ID: 22417841
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Abou Khalil Y; Marmontel O; Ferrières J; Paillard F; Yelnik C; Carreau V; Charrière S; Bruckert E; Gallo A; Giral P; Philippi A; Bluteau O; Boileau C; Abifadel M; Di-Filippo M; Carrié A; Rabès JP; Varret M
    Int J Mol Sci; 2022 May; 23(10):. PubMed ID: 35628605
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phenotypic variability in 4 homozygous familial hypercholesterolemia siblings compound heterozygous for LDLR mutations.
    Rabacchi C; Bigazzi F; Puntoni M; Sbrana F; Sampietro T; Tarugi P; Bertolini S; Calandra S
    J Clin Lipidol; 2016; 10(4):944-952.e1. PubMed ID: 27578127
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Homozygous Familial Hypercholesterolemia in Spain: Prevalence and Phenotype-Genotype Relationship.
    Sánchez-Hernández RM; Civeira F; Stef M; Perez-Calahorra S; Almagro F; Plana N; Novoa FJ; Sáenz-Aranzubía P; Mosquera D; Soler C; Fuentes FJ; Brito-Casillas Y; Real JT; Blanco-Vaca F; Ascaso JF; Pocovi M
    Circ Cardiovasc Genet; 2016 Dec; 9(6):504-510. PubMed ID: 27784735
    [TBL] [Abstract][Full Text] [Related]  

  • 8. APOE p.Leu167del mutation in familial hypercholesterolemia.
    Awan Z; Choi HY; Stitziel N; Ruel I; Bamimore MA; Husa R; Gagnon MH; Wang RH; Peloso GM; Hegele RA; Seidah NG; Kathiresan S; Genest J
    Atherosclerosis; 2013 Dec; 231(2):218-22. PubMed ID: 24267230
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Spectrum of mutations in Italian patients with familial hypercholesterolemia: New results from the LIPIGEN study.
    Pirillo A; Garlaschelli K; Arca M; Averna M; Bertolini S; Calandra S; Tarugi P; Catapano AL;
    Atheroscler Suppl; 2017 Oct; 29():17-24. PubMed ID: 28965616
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lipid phenotype and heritage pattern in families with genetic hypercholesterolemia not related to LDLR, APOB, PCSK9, or APOE.
    Jarauta E; Pérez-Ruiz MR; Pérez-Calahorra S; Mateo-Gallego R; Cenarro A; Cofán M; Ros E; Civeira F; Tejedor MT
    J Clin Lipidol; 2016; 10(6):1397-1405.e2. PubMed ID: 27919357
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Homozygous familial hypercholesterolemia in Italy: Clinical and molecular features.
    Bertolini S; Calandra S; Arca M; Averna M; Catapano AL; Tarugi P;
    Atherosclerosis; 2020 Nov; 312():72-78. PubMed ID: 32977124
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Causative mutations and premature cardiovascular disease in patients with heterozygous familial hypercholesterolaemia.
    Rubba P; Gentile M; Marotta G; Iannuzzi A; Sodano M; De Simone B; Jossa F; Iannuzzo G; Giacobbe C; Di Taranto MD; Fortunato G
    Eur J Prev Cardiol; 2017 Jul; 24(10):1051-1059. PubMed ID: 28353356
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cosegregation of serum cholesterol with cholesterol intestinal absorption markers in families with primary hypercholesterolemia without mutations in LDLR, APOB, PCSK9 and APOE genes.
    Baila-Rueda L; Pérez-Ruiz MR; Jarauta E; Tejedor MT; Mateo-Gallego R; Lamiquiz-Moneo I; de Castro-Orós I; Cenarro A; Civeira F
    Atherosclerosis; 2016 Mar; 246():202-7. PubMed ID: 26802983
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular genetics of familial hypercholesterolemia in Israel-revisited.
    Durst R; Ibe UK; Shpitzen S; Schurr D; Eliav O; Futema M; Whittall R; Szalat A; Meiner V; Knobler H; Gavish D; Henkin Y; Ellis A; Rubinstein A; Harats D; Bitzur R; Hershkovitz B; Humphries SE; Leitersdorf E
    Atherosclerosis; 2017 Feb; 257():55-63. PubMed ID: 28104544
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Next-generation sequencing to confirm clinical familial hypercholesterolemia.
    Reeskamp LF; Tromp TR; Defesche JC; Grefhorst A; Stroes ESG; Hovingh GK; Zuurbier L
    Eur J Prev Cardiol; 2021 Jul; 28(8):875-883. PubMed ID: 34298557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proprotein convertase subtilisin/kexin 9 V4I variant with LDLR mutations modifies the phenotype of familial hypercholesterolemia.
    Ohta N; Hori M; Takahashi A; Ogura M; Makino H; Tamanaha T; Fujiyama H; Miyamoto Y; Harada-Shiba M
    J Clin Lipidol; 2016; 10(3):547-555.e5. PubMed ID: 27206942
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of rare variants in autosomal dominant hypercholesterolemia causing genes.
    Calandra S; Tarugi P; Bertolini S
    Curr Opin Lipidol; 2017 Jun; 28(3):267-272. PubMed ID: 28323660
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ABCG5 and ABCG8 genetic variants in familial hypercholesterolemia.
    Reeskamp LF; Volta A; Zuurbier L; Defesche JC; Hovingh GK; Grefhorst A
    J Clin Lipidol; 2020; 14(2):207-217.e7. PubMed ID: 32088153
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of a novel LDLR disease-causing variant using capture-based next-generation sequencing screening of familial hypercholesterolemia patients in Taiwan.
    Hsiung YC; Lin PC; Chen CS; Tung YC; Yang WS; Chen PL; Su TC
    Atherosclerosis; 2018 Oct; 277():440-447. PubMed ID: 30270083
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical characterization and mutation spectrum of German patients with familial hypercholesterolemia.
    Grenkowitz T; Kassner U; Wühle-Demuth M; Salewsky B; Rosada A; Zemojtel T; Hopfenmüller W; Isermann B; Borucki K; Heigl F; Laufs U; Wagner S; Kleber ME; Binner P; März W; Steinhagen-Thiessen E; Demuth I
    Atherosclerosis; 2016 Oct; 253():88-93. PubMed ID: 27596133
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.